4- https://doi.org/10.1186/s13046-024-03247-w
Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD
Translate Article 
Take Notes Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a second-line treatment with curative potential for leukemia patients. However, the prognosis of allo-HSCT patients with disease relapse or graft-versus-host disease (GvHD) is poor. CD4+ or CD8+ conventional T (Tconv) cells are critically involved in mediating anti-leukemic immune responses to prevent relapse and detrimental GvHD. Hence, treatment for one increases the risk of the other. Thus, therapeutic strategies that can address relapse and GvHD are considered the Holy Grail of allo-HSCT. CD3+CD4−CD8− double-negative T cells (DNTs) are unconventional mature T cells with potent anti-leukemia effects with “off-the-shelf” potential. A phase I clinical trial demonstrated the feasibility, safety, and potential efficacy of allogeneic DNT therapy for patients with relapsing acute myeloid leukemia (AML) post-allo-HSCT. Here, we studied the impact of DNTs on the anti-leukemic and GvHD-inducing activities of Tconv cells. DNTs synergized with Tconv cells to mediate superior anti-leukemic activity. Mechanistically, DNTs released soluble factors which activated and evoked potent anti-leukemic activities of Tconv cells. In contrast, DNTs suppressed GvHD-inducing activities of Tconv cells in a CD18-dependent manner by mediating cytotoxicity against proliferative Tconv cells. The seemingly opposite immunological activities of DNTs were dictated by the presence or absence of AML cells. Collectively, these results support the potential of DNTs as an adjuvant to allo-HSCT to address both disease relapse and GvHD.
- Research Article
- 29
- 10.1016/j.bbmt.2010.10.031
- Nov 1, 2010
- Biology of Blood and Marrow Transplantation
Minimal Residual Disease following Allogeneic Hematopoietic Stem Cell Transplantation
- Abstract
- 1
- 10.1182/blood.v112.11.3516.3516
- Nov 16, 2008
- Blood
Only MHC-Identical Donor CD4+CD25+ Regulatory T Cells Convey Full Protection from Lethal Graft-Versus-Host Disease
- Abstract
- 4
- 10.1182/blood.v124.21.990.990
- Dec 6, 2014
- Blood
CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
- Abstract
- 10.1182/blood.v114.22.709.709
- Nov 20, 2009
- Blood
Reciprocal Interactions Between Conventional CD4 T Cells and Regulatory T Cells Alter the Properties of Regulatory T Cells and Promote the Development of IL-17 Producing Cells.
- Research Article
- 10.1097/01.cot.0000512060.75241.ec
- Jan 10, 2017
- Oncology Times
Cellular Immunotherapies for Leukemia Patients
- Research Article
- 31
- 10.1016/j.exphem.2012.06.003
- Jun 12, 2012
- Experimental Hematology
Impact of anti-HLA antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens
- Abstract
- 6
- 10.1182/blood-2021-149751
- Nov 5, 2021
- Blood
Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy
- Abstract
- 2
- 10.1182/blood.v116.21.3480.3480
- Nov 19, 2010
- Blood
A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report.
- Abstract
- 10.1182/blood-2019-125592
- Nov 13, 2019
- Blood
Head-to-Head Comparison of Haploidentical HSCT Strategies for Hematologic Malignancies: Phase III Hatcy Study of T-Cell-Depleted HSCT with Adjunctive ATIR101 Versus T-Cell-Replete HSCT with Post‐Transplant Cyclophosphamide
- Research Article
- 97
- 10.1016/j.bbmt.2010.05.007
- May 26, 2010
- Biology of Blood and Marrow Transplantation
Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- Research Article
- 61
- 10.1016/j.exphem.2008.01.017
- Mar 17, 2008
- Experimental Hematology
Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire
- Abstract
- 3
- 10.1182/blood.v124.21.729.729
- Dec 6, 2014
- Blood
Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT
- Abstract
- 10.1016/s1525-0016(16)33317-2
- May 1, 2016
- Molecular Therapy
508. IL-33/ST2 Triggering of IL-9-Secreting T Cells: From Proteomics to Therapeutics
- Abstract
- 10.1182/blood.v116.21.1294.1294
- Nov 19, 2010
- Blood
Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) In Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Interim-Analysis From the AZARELA-Trial (NCT-00795548).
- Abstract
- 10.1182/blood-2024-199632
- Nov 5, 2024
- Blood
Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
